Triumvira is Creating a Different Picture for Cancer Patients

Triumvira Immunologics has an alternative to chimeric antigen receptor (CAR) and T cell receptor (TCR) therapies – one that has the potential to overcome challenges like lack of persistence in solid tumors, premature exhaustion and toxicities.